Clinical trials: C. Difficile
Clostridium Difficile
To Determine the Feasibility of a Fidaxomicin Study in Neonates and to Assess C. Difficile (Clostridium Difficile) Involvement in the Pathogenesis
The objective of this multi-center, prospective observational study is to determine the feasibility of a potential interventional study with fidaxomicin.
- Trial name
- DAISY (NCT01533844)
- Where
- 9 sites in France, Germany and 2 more
- Volunteers
- 1 people
- Sponsor
- Astellas Pharma Europe B.V.
Recurrent Clostridium Difficile Infection
Lyophilized Fecal Microbiota Transplantation for Recurrent Clostridioides Difficile Infection
The primary goal is to study participants with recurrent C. difficile infection (CDI) treated with lyophilized fecal microbiota transplantation (FMT). The safety, clinical response and relapse rate in patients will be assessed.
- Trial name
- NCT03834038
- Testing
- Lyophilized Fecal Microbiota Transplantation
- Where
- Canada
- Volunteers
- 158 people
- Sponsor
- Vancouver Island Health Authority
Aspergillosis, Candidemia
UARK 2009-99 A Non-interventional Observational Study of Infectious Complications in Cancer Patients
OBSERVATIONAL STUDY OF INFECTIOUS COMPLICATIONS IN CANCER PATIENTS
- Conditions
- Aspergillosis, Candidemia, C. Difficile
- Trial name
- NCT01622595
- Where
- United States
- Sponsor
- University of Arkansas
Enterocolitis Clostridium Difficile Recurrent
FMT Delivered by Capsule Versus Colonoscopy for Recurrent C. Diff
Delivery of FMT by upper route, including gastroscopy, nasogastric/ nasojejunal tube, and lower route, including retention enema, sigmoidoscopy, or colonoscopy have all been utilized successfully.
- Trial name
- NCT02254811
- Testing
- Fecal Microbiota Transplant
- Where
- 2 sites in Canada
- Volunteers
- 116 people
- Sponsor
- University of Alberta
Clostridium Difficile Infection
Oral Vancomycin to Prevent Recurrent C Difficile Infection With Antibiotics
This study will assess the efficacy of oral vancomycin prophylaxis in preventing recurrent Clostridium difficile infection in hospitalized patients requiring oral or intravenous antibiotics for a suspected or confirmed bacterial…
- Trial name
- NCT03466502
- Testing
- Oral Vancomycin
- Where
- United States
- Volunteers
- 104 people
- Sponsor
- University of Nevada, Reno
Infection With AmpC Beta-lactamase Producing Enterobacterales
Clinical Comparison of Treatment Strategies in AmpC Beta-lactamase Producing Enterobacterales in a Swiss Tertiary Care Hospital
This study is to investigate the recent epidemiological trends and the treatment outcome in terms of the length of hospital stay, the relevant renal and neurological side effects, risk factors for developing these side effects…
- Trial name
- AmpCstratBasel (NCT04577989)
- Testing
- data collection
- Where
- Switzerland
- Volunteers
- 270 people
- Sponsor
- University Hospital, Basel, Switzerland
C. Difficile Infection
Prospective Study of Clostridium Difficile in Children Undergoing Colonoscopy
The investigators found that community acquired C. diff occurs in children undergoing a colonoscopy. When they were treated their symptoms got better. But, the investigators do not know if the treatment for the C.
- Trial name
- c diff (NCT01472978)
- Testing
- metronidazole
- Where
- United States
- Sponsor
- State University of New York at Buffalo
Clostridium Difficile Infection
Fecal Transplantation for Primary Clostridium Difficile Infection
In this randomized controlled trial the investigators want to compare the effect of one-time rectal instillation of fecal microbiota transplantation, compared to a ten-day antibiotic course for the treatment of primary…
- Trial name
- COLONIZE (NCT03796650)
- Testing
- Fecal microbiota transplantation, Vancomycin
- Where
- 18 sites in Norway
- Volunteers
- 104 people
- Sponsor
- Oslo University Hospital
Ventilator Associated Pneumonia, Infections
Probiotics to Prevent Severe Pneumonia and Endotracheal Colonization Trial
Probiotics are commercially available live bacteria thought to have health benefits when ingested. A literature review of probiotic studies in the intensive care unit (ICU) found that in patients who receive probiotics, there is…
- Conditions
- Ventilator Associated Pneumonia, Infections, C-Difficile, Antibiotic-associated Diarrhea
- Trial name
- PROSPECT (NCT02462590)
- Testing
- L. rhamnosus GG - Probiotic
- Where
- 44 sites in United States, Canada and 1 more
- Volunteers
- 2,650 people
- Sponsor
- McMaster University
Intestinal C. Difficile
Probiotic Intervention With Elderly Subjects
The study objective is to evaluate the effect of probiotic on faecal Clostridium difficile levels of elderly subjects.
- Trial name
- NCT01475942
- Testing
- Probiotic
- Where
- Finland
- Volunteers
- 104 people, healthy volunteers welcome
- Sponsor
- Danisco
Clostridium Difficile Infection
MET-2 Clinical Study for Recurrent Clostridium Difficile Infection (CDI)
MET-2 clinical study is an Open label, single center, multiple dose pilot study of 19 patients. The study is designed to measure the resolution of diarrhea as well as the feasibility of administration and safety of MET-2 for the…
- Trial name
- NCT02865616
- Testing
- MET-2, Vancomycin
- Where
- Canada
- Volunteers
- 19 people
- Sponsor
- NuBiyota
Recurrent Clostridium Difficile Infection, Clostridium Difficile Infection
Efficacy of Oral Vancomycin Prophylaxis for Prevention of Recurrent Clostridium Difficile Infection
This study evaluates the efficacy of prophylaxis with oral vancomycin for preventing recurrent Clostridium difficile Infection (CDI) in patients who have experienced at least one CDI episode in the last 180 days and are receiving…
- Conditions
- Recurrent Clostridium Difficile Infection, Clostridium Difficile Infection, CDI, C.Difficile Diarrhea
- Trial name
- NCT03462459
- Testing
- Vancomycin
- Where
- 2 sites in United States
- Volunteers
- 79 people
- Sponsor
- University of Wisconsin, Madison
Recurrent Clostridium Difficile Infection
Microbiota Restoration Therapy for Recurrent Clostridium Difficile-associated Diarrhea
This study will assess the safety of a new biologic drug, RBX2660 (microbiota suspension) as a treatment for recurrent Clostridium difficile-associated diarrhea (CDAD), which is the primary symptom of recurrent Clostridium…
- Trial name
- PUNCH CD (NCT01925417)
- Testing
- RBX2660 (microbiota suspension)
- Where
- 13 sites in United States
- Volunteers
- 34 people
- Sponsor
- Rebiotix Inc.
Clostridium Difficile Infection
Harnessing the Healthy Gut Microbiota to Cure Patients With Recurrent C. Difficile Infection
CDI (Clostridium difficile infection) causes diarrheal illness and can cause colitis which may be fatal. A patient being treated for CDI has a 10-25% chance of developing relapse. Recurrent CDI is on the rise.
- Trial name
- NCT01372943
- Testing
- "synthetic stool" or pure cultures of probiotic intestinal bacteria
- Where
- Canada
- Volunteers
- 4 people
- Sponsor
- Queen's University
Clostridium Difficile, Inflammatory Bowel Disease
Fecal Microbiome Transplant
Fecal Microbiota Transplant (FMT) in pediatric patients with recurrent C. Difficile with or without Inflammatory Bowel Disease (IBD) The aims of this study are to determine the safety and efficacy of FMT treatment in pediatric…
- Conditions
- Clostridium Difficile, Inflammatory Bowel Disease, Crohn's Disease, Ulcerative Colitis
- Trial name
- NCT02636517
- Testing
- Fecal Microbiota Transplant
- Where
- United States
- Volunteers
- 250 people
- Sponsor
- Judith Kelsen
Clostridium Difficile Infection
FMT Versus Antimicrobials for Initial Treatment of Recurrent CDI
The purpose of the study is to determine the safety and efficacy of Fecal Microbiota Transplant (FMT) for the treatment of the recurrence of Clostridium difficile infection (CDI) as compared to standard antibiotic therapy.
- Trial name
- NCT02255305
- Testing
- FMT, Antimicrobials
- Where
- United States
- Volunteers
- 6 people
- Sponsor
- Endeavor Health
Clostridia Difficile Colitis, Clostridium; Sepsis
Comparing the Effectiveness of IV Bezlotoxumab Versus Placebo in Decreasing Morbidity and Mortality in Patients With Fulminant C. Diff Requiring Surgery.
A new medication, Bezlotoxumab, has been approved for treatment of recurrent Clostridium difficile diarrhea by the U.S. Food and Drug Administration. The way this new medication works, is by binding the toxin produced by C.
- Trial name
- NCT03756454
- Testing
- Bezlotoxumab, Normal Saline
- Where
- United States
- Volunteers
- 5 people
- Sponsor
- Ohio State University
Clostridium Difficile Infection Recurrence
Efficacy, Safety, and Tolerability Study of Oral Full-Spectrum MicrobiotaTM (CP101) in Subjects With Recurrent C. Diff
Subjects with recurrent C. difficile infection will receive an oral dose of CP101 capsules one time in Treatment Group I or matching placebo one time in Treatment Group II.
- Trial name
- PRISM3 (NCT03110133)
- Testing
- Full Spectrum Microbiota
- Where
- 58 sites in United States, Canada
- Volunteers
- 206 people
- Sponsor
- Finch Research and Development LLC.
Clostridium Difficile Infection
Treatment of C. Difficile Infection With Fecal Microbiota Transplantation (FMT)
The purpose of this study is to treat children with severe, moderate, resistant or relapsing C. difficile infection and to determine the changes in the intestinal microbiome (all of the bacteria living in the intestines) in…
- Trial name
- NCT01842347
- Testing
- Fecal microbiota
- Where
- United States
- Sponsor
- Medical College of Wisconsin
Clostridium Difficile
Intestinal Lavage for the Treatment of Severe C. Difficile Infections
Clostridium Difficile infections (CDIs) are treated initially with antibiotic therapy and supportive care, with surgical intervention reserved for patients with significant systemic toxicity or perforation.
- Trial name
- NCT02466698
- Testing
- Intestinal Lavage, Vancomycin, PEG
- Where
- Canada
- Volunteers
- 20 people
- Sponsor
- London Health Sciences Centre Research Institute OR Lawson Research Institute of St. Joseph's